Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells.

@article{FernandezRuiz2011TreatmentOM,
  title={Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells.},
  author={Veronica Fernandez-Ruiz and Milosz Piotr Kawa and Carmen Berasain and Mar{\'i}a I{\~n}iguez and Volker Schmitz and Eduardo Mart{\'i}nez-Ans{\'o} and Mercedes I{\~n}arrairaegui and Ignacio Herrero and Bruno Sangro and Delia D'Avola and J. Quiroga and Cheng Qian and Jes{\'u}s Prieto},
  journal={Journal of hepatology},
  year={2011},
  volume={55 4},
  pages={828-37}
}
BACKGROUND & AIMS Cell therapy has been used to attenuate liver injury. Here we evaluated whether genetic engineering of either bone marrow-derived mononuclear cells (MNC) or endothelial progenitor cells (EPC) many enhance their hepatoprotective properties. METHODS Mice with ConA-induced hepatitis or with lethal fulminant hepatitis resulting from administration of an adenovirus encoding CD40L (AdCD40L) received an intra-splenic injection of saline or 2 × 10(6) unmodified MNC or EPC or the… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…